199 related articles for article (PubMed ID: 27113955)
1. Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials.
Kunwar S; Devkota AR; Ghimire DK
Rheumatol Int; 2016 Aug; 36(8):1077-87. PubMed ID: 27113955
[TBL] [Abstract][Full Text] [Related]
2. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Weinblatt ME; Genovese MC; Ho M; Hollis S; Rosiak-Jedrychowicz K; Kavanaugh A; Millson DS; Leon G; Wang M; van der Heijde D
Arthritis Rheumatol; 2014 Dec; 66(12):3255-64. PubMed ID: 25223724
[TBL] [Abstract][Full Text] [Related]
3. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.
Scott DL
Drugs; 2011 Jun; 71(9):1121-32. PubMed ID: 21711059
[TBL] [Abstract][Full Text] [Related]
4. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
Genovese MC; Kavanaugh A; Weinblatt ME; Peterfy C; DiCarlo J; White ML; O'Brien M; Grossbard EB; Magilavy DB
Arthritis Rheum; 2011 Feb; 63(2):337-45. PubMed ID: 21279990
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study.
Tanaka Y; Millson D; Iwata S; Nakayamada S
Rheumatology (Oxford); 2021 Jun; 60(6):2884-2895. PubMed ID: 33254235
[TBL] [Abstract][Full Text] [Related]
6. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.
Weinblatt ME; Kavanaugh A; Genovese MC; Jones DA; Musser TK; Grossbard EB; Magilavy DB
J Rheumatol; 2013 Apr; 40(4):369-78. PubMed ID: 23378467
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA).
Maringwa J; Kågedal M; Hamrén UW; Martin P; Cox E; Hamrén B
J Clin Pharmacol; 2015 Mar; 55(3):328-35. PubMed ID: 25280085
[TBL] [Abstract][Full Text] [Related]
8. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist.
Genovese MC; van der Heijde DM; Keystone EC; Spindler AJ; Benhamou C; Kavanaugh A; Fudman E; Lampl K; O'Brien C; Duffield EL; Poiley J; Weinblatt ME
J Rheumatol; 2014 Nov; 41(11):2120-8. PubMed ID: 25225285
[TBL] [Abstract][Full Text] [Related]
9. Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.
Kunwar S; Dahal K; Sharma S
Rheumatol Int; 2016 Aug; 36(8):1065-75. PubMed ID: 27105880
[TBL] [Abstract][Full Text] [Related]
10. The status of fostamatinib in the treatment of rheumatoid arthritis.
Morales-Torres J
Expert Rev Clin Immunol; 2012 Sep; 8(7):609-15. PubMed ID: 23078058
[TBL] [Abstract][Full Text] [Related]
11. Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
Scott IC; Scott DL
Drugs; 2014 Mar; 74(4):415-22. PubMed ID: 24610702
[TBL] [Abstract][Full Text] [Related]
12. The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial.
Kitas GD; Abreu G; Jedrychowicz-Rosiak K; Miller JL; Nakov R; Panfilov S; Vencovsky J; Wang M; Weinblatt ME; White WB
J Am Soc Hypertens; 2014 Nov; 8(11):780-90. PubMed ID: 25455003
[TBL] [Abstract][Full Text] [Related]
13. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Weinblatt ME; Kavanaugh A; Genovese MC; Musser TK; Grossbard EB; Magilavy DB
N Engl J Med; 2010 Sep; 363(14):1303-12. PubMed ID: 20879879
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis.
Nijjar JS; Tindell A; McInnes IB; Siebert S
Rheumatology (Oxford); 2013 Sep; 52(9):1556-62. PubMed ID: 23861534
[TBL] [Abstract][Full Text] [Related]
15. Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.
Kunwar S; Collins CE; Constantinescu F
Clin Rheumatol; 2018 Oct; 37(10):2611-2620. PubMed ID: 30006916
[TBL] [Abstract][Full Text] [Related]
16. Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinib.
Boström E; Öhrn F; Hanze E; Sandström M; Martin P; Wählby-Hamrén U
J Clin Pharmacol; 2014 Dec; 54(12):1337-46. PubMed ID: 24895144
[TBL] [Abstract][Full Text] [Related]
17. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
Weinblatt ME; Kavanaugh A; Burgos-Vargas R; Dikranian AH; Medrano-Ramirez G; Morales-Torres JL; Murphy FT; Musser TK; Straniero N; Vicente-Gonzales AV; Grossbard E
Arthritis Rheum; 2008 Nov; 58(11):3309-18. PubMed ID: 18975322
[TBL] [Abstract][Full Text] [Related]
18. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Bajpai M
IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Multiple Dosages of Fostamatinib in Adult Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Kang Y; Jiang X; Qin D; Wang L; Yang J; Wu A; Huang F; Ye Y; Wu J
Front Pharmacol; 2019; 10():897. PubMed ID: 31474860
[No Abstract] [Full Text] [Related]
20. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.
Bussel J; Arnold DM; Grossbard E; Mayer J; Treliński J; Homenda W; Hellmann A; Windyga J; Sivcheva L; Khalafallah AA; Zaja F; Cooper N; Markovtsov V; Zayed H; Duliege AM
Am J Hematol; 2018 Jul; 93(7):921-930. PubMed ID: 29696684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
